Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Wilson

Showing results (371-380 of 387) with videos related to

Pageof 39
Sort By:
Cancers|August 27, 2021
Plasma Based Protein Signatures Associated with Small Cell Lung CancerJohannes F Fahrmann, Hiroyuki Katayama, Ehsan Irajizad, et al.
British Journal of Haematology|November 9, 2021
Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMTG Gutiérrez-García, C Martínez, A Boumendil, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 18, 2018
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel AgentsFiroozeh Sahebi, Simona Iacobelli, Giulia Sbianchi, et al.
Bone Marrow Transplantation|December 1, 2023
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working PartyJesús Duque-Afonso, Jürgen Finke, Maud Ngoya, et al.
Cancer Research|January 28, 2010
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancerEvanthia Galanis, Lynn C Hartmann, William A Cliby, et al.
Bone Marrow Transplantation|May 13, 2024
Correction: Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMTMarie Robin, Simona Iacobelli, Linda Koster, et al.
Bone Marrow Transplantation|August 5, 2023
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMTRémi Tilmont, Ibrahim Yakoub-Agha, Diderik-Jan Eikema, et al.
Bone Marrow Transplantation|February 16, 2022
Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMTJoanna Drozd-Sokołowska, Luuk Gras, Nienke Zinger, et al.
Haematologica|January 11, 2024
Autologous hematopoietic cell transplantation for T-cell prolymphocytic leukemia: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTJoanna Drozd-Sokolowska, Luuk Gras, Linda Koster, et al.
Haematologica|June 30, 2022
Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modelingSarah Lawless, Simona Iacobelli, Nina Simone Knelange, et al.
Pageof 39

Showing results (371-380 of 387) with videos related to

Sort By:
Pageof 39
Cancers|August 27, 2021
Plasma Based Protein Signatures Associated with Small Cell Lung CancerJohannes F Fahrmann, Hiroyuki Katayama, Ehsan Irajizad, et al.
British Journal of Haematology|November 9, 2021
Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMTG Gutiérrez-García, C Martínez, A Boumendil, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 18, 2018
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel AgentsFiroozeh Sahebi, Simona Iacobelli, Giulia Sbianchi, et al.
Bone Marrow Transplantation|December 1, 2023
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working PartyJesús Duque-Afonso, Jürgen Finke, Maud Ngoya, et al.
Cancer Research|January 28, 2010
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancerEvanthia Galanis, Lynn C Hartmann, William A Cliby, et al.
Bone Marrow Transplantation|May 13, 2024
Correction: Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMTMarie Robin, Simona Iacobelli, Linda Koster, et al.
Bone Marrow Transplantation|August 5, 2023
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMTRémi Tilmont, Ibrahim Yakoub-Agha, Diderik-Jan Eikema, et al.
Bone Marrow Transplantation|February 16, 2022
Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMTJoanna Drozd-Sokołowska, Luuk Gras, Nienke Zinger, et al.
Haematologica|January 11, 2024
Autologous hematopoietic cell transplantation for T-cell prolymphocytic leukemia: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTJoanna Drozd-Sokolowska, Luuk Gras, Linda Koster, et al.
Haematologica|June 30, 2022
Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modelingSarah Lawless, Simona Iacobelli, Nina Simone Knelange, et al.
Pageof 39